CD64 Chimeric Receptor Enhancing ADCC in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using monoclonal antibodies for solid and hematologic malignancies face limitations in enhancing antibody-dependent cellular cytotoxicity (ADCC), as existing therapies rely primarily on Fcγ receptor-dependent mechanisms, which may not be sufficient for all cancer types.
Innovation Solution
Development of chimeric receptors, specifically CD64 chimeric receptors, that include an extracellular ligand binding domain of CD64, a transmembrane domain, and an intracellular domain, which are expressed in human T lymphocytes to enhance ADCC by redirecting immune cells to recognize and kill cancer cells independently of antibody ligation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Fcγ receptor-dependent mechanisms are used for cancer treatment, then antibody-dependent cellular cytotoxicity (ADCC) is achieved, but the therapeutic effectiveness is limited and not sufficient for all cancer types
Solution Approach 1:
The patent segments the FcγR system into multiple distinct receptor types (FcγRI/CD64, FcγRIIA/CD32A, FcγRIIIA/CD16A, FcγRIIB/CD32B) with different activation properties. By expressing these segmented receptor types on different immune cell populations, the system achieves both reliable ADCC through specialized receptors and versatility across cancer types by matching specific receptors to appropriate cell therapies.
Solution Approach 2:
The patent creates a universal platform where multiple FcγR types can be expressed on engineered immune cells to provide multi-functional anti-tumor activity. The system universally targets the Fc portion of therapeutic antibodies, enabling a single platform to address diverse cancer types through different FcγR-expressing cell products.
2Reliability
If existing FcγR-dependent therapies are used, then ADCC is mediated through FcγRI, FcγRIIA, FcγRIIIA, or FcγRIIB, but the mechanism may not be sufficient for all malignancies
Solution Approach 1:
The patent applies local quality by assigning specific FcγR types to specific immune cell types based on their functional characteristics. For example, FcγRI (CD64) with high affinity is expressed on cells requiring strong binding, while FcγRIIIA (CD16A) is used on NK cells where it naturally resides. This localized optimization of receptor-expression matching ensures reliable ADCC while adapting to different malignancy requirements.
3Strength
If monoclonal antibodies are used to treat solid and hematologic malignancies, then anti-tumor activity is achieved through signaling pathway interference and ADCC, but enhancement of ADCC remains limited
Solution Approach 1:
The patent introduces engineered immune cells expressing specific FcγR types as intermediaries between therapeutic antibodies and tumor cells. These intermediary cells enhance ADCC by providing optimized FcγR expression profiles that improve antibody binding and cellular activation, thereby strengthening anti-tumor activity and increasing ADCC productivity beyond what standard monotherapy achieves.
Data Source
AI summary
The present invention provides compositions and methods for treating cancer in a human. The invention includes a chimeric receptor which comprises an CD64 binding domain, a transmembrane domain, and a CD3zeta signaling domain.